Tony Zhang is a co-founder and CEO for Tyligand Bioscience. He has a PhD degree from Purdue University under the direction of Professor Ei-ichi Negishi. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia.
Dr. Zhang has led multi-disciplined teams in drug development across several therapeutic areas, and has published more than 60 articles and monographs in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is a named inventor for 26 international patents and an editorial board member for the journal Organic Process Research and Development, co-published by the American Chemical Society and the Royal Society of Chemistry. He has served as the Chairman of the Board for the Bayhelix Group, adjunct professor or advisor for several universities, not-for-profit organizations, and venture investment firms.